EPL – still essential in non-alcoholic fatty liver disease Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
non-alcoholic fatty liver disease, essential phospholipids, non-alcoholic fatty liver, non-alcoholic steatohepatitis
Main Article Content
Abstract
The incidence of non-alcoholic fatty liver disease has increased dramatically over the past 30 years due to lifestyle changes leading to an increase in the incidence of obesity, metabolic syndrome and its individual components. However, until now no drug has been officially registered for its treatment. But in practice we are using many substances with effectiveness confirmed in research and practice. The most effective are essential phospholipids that improve the liver’s biochemical function, reduce inflammation, steatosis and fibrosis, and reduce hyperlipidemia, which is one of the important risk factors.
Article Details
How to Cite
Kukla, M., & Cisek, K. (2018). EPL – still essential in non-alcoholic fatty liver disease. Medycyna Faktow (J EBM), 11(3(40), 228-231. https://doi.org/10.24292/01.MF.0318.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kuntz E., Kuntz H.D. (red.): Hepatology. Wyd. 3. Springer, Heidelberg 2008: 894-896.
2. Gundermann K.J., Kuenker A., Kuntz E., Drozdzik M.: Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63(3): 643-659.
3. Arvind N., Savaikar P., Rajkumar J.S.: Therapy for NAFLD – comparative study of essential phospholipids vs ursodeoxycholic acid. Ind. J. Clin. Pract. 2006; 16(10): 21-24.
4. Hempfling W., Dilger K., Beuers U.: Systematic review: ursodeoxycholic acid-adverse effects and drug interactions. Aliment. Pharmacol. Ther. 2003; 18(10): 963-972.
5. Bedogni G., Miglioli L., Masutti F. et al.: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
6. Younossi Z.M., Stepanova M., Afendy M. et al.: Changes in the prevalence of the most common causes of chronic liver diseases In the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9: 524-530.
7. Marchesini G., Day C.P., Dufour J.-F. et al.: EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.
2. Gundermann K.J., Kuenker A., Kuntz E., Drozdzik M.: Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63(3): 643-659.
3. Arvind N., Savaikar P., Rajkumar J.S.: Therapy for NAFLD – comparative study of essential phospholipids vs ursodeoxycholic acid. Ind. J. Clin. Pract. 2006; 16(10): 21-24.
4. Hempfling W., Dilger K., Beuers U.: Systematic review: ursodeoxycholic acid-adverse effects and drug interactions. Aliment. Pharmacol. Ther. 2003; 18(10): 963-972.
5. Bedogni G., Miglioli L., Masutti F. et al.: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
6. Younossi Z.M., Stepanova M., Afendy M. et al.: Changes in the prevalence of the most common causes of chronic liver diseases In the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9: 524-530.
7. Marchesini G., Day C.P., Dufour J.-F. et al.: EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.